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We investigated the effects of acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) on a
lymphoblastoid cell line dually infected with Epstein-Barr virus and herpes simplex virus (HSV) type 1. The
numbers of Epstein-Barr virus genomes were reduced during 70 days of treatment with either drug. Both drugs
suppressed HSV replication in a dose-related manner. In the continued presence of the drugs, HSV developed
resistance, rapidly to acyclovir and much more slowly to 30 p,M DHPG. Analysis of HSV glycoprotein C
production and viral DNA showed that treatment with 100 p,M DHPG eliminated HSV production, curing the
cell line of HSV persistent infection.
Treatment of both herpes simplex virus (HSV) and Ep-
stein-Barr virus (EBV) infections in humans with 9-(2-
hydroxyethoxymethyl)guanine (acyclovir; ACV) is proble-
matic since viral replication is only suppressed when the
drug is present (5, 18); neither virus can be eradicated by
treatment with ACV.
We studied the effects of ACV and 9-(1,3-dihydroxy-2-
propoxymethyl)guanine (DHPG) on a human lymphoblas-
toid cell line dually infected with HSV type 1 and EBV (19,
21) during 70 days of therapy and up to 360 days after release
from the drug. When initially characterized, less than 1% of
the cells in this line were found, by infectious-center assay,
to produce HSV, although 80% of the cells had HSV
antigens (19). This cell system represents true HSV persist-
ent infection, with levels of HSV in the supernatant fluid
ranging from 106 to 107 PFU/106 cells, documented for years
without spontaneous curing of either HSV or EBV infection.
The disparity between the number of cells producing HSV
and the number of cells with HSV antigens suggests that,
analogous to clinical HSV infection, there are cells which are
productive ofHSV and cells in which the virus is persistent.
To determine the effect of the drugs on cell growth kinetics
and virus production, equal numbers of viable cells were
suspended in 30 ,uM ACV, 30 ,uM DHPG, 100 p.M ACV, or
100 ,uM DHPG or were not treated. As shown in Fig. 1, 100
,um DHPG was toxic, with the number of viable cells
determined by trypan blue exclusion dropping 10-fold below
the number of viable untreated control cells by day 24 of
treatment. With cells exposed to 30 or 100 ,uM ACV or 30
,uM DHPG, their numbers increased fivefold over the num-
ber of control cells in the same period, presumably because
of protection from HSV cytopathic effects.
The amount of infectious virus released into the superna-
tant fluid, as determined by plaque assay with Vero cells and
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an agarose overlay, fluctuated as a function of cell density
(Fig. 2). Calculating HSV PFU per cell permitted compari-
son between different flasks. Within 10 days of treatment
with 30 or 100 ,uM ACV, the numbers of HSV PFU were
reduced 450- and 1,780-fold, respectively. DHPG at 30 ,uM
had maximal effect at 14 days, with a 317,000-fold reduction
of the HSV titer. This effect was confirmed by the reduction
of the number of cells expressing glycoprotein C, a late viral
gene product associated with HSV replication, from 22 to
less than 10% of the cells by 14 days. Continued treatment of
the cells with 30 or 100 ,uM ACV resulted in the generation
of apparently drug-resistant HSV by day 24, as evidenced by
the return of HSV titers to the control levels (Fig. 2). In
contrast, it took 70 days for drug-resistant HSV to develop in
cells treated with 30 ,uM DHPG.
Production of resistant HSV was confirmed by increases
in the 50% effective dose (ED50), calculated from a plot
relating percent surviving plaques in a plaque reduction
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FIG. 1. Growth kinetics of dually infected cells treated with
antiviral drugs. Symbols: 0, untreated cells; A, 30 siM ACV-treated
cells; V, 100 ,uM ACV-treated cells; *, 30 ,uM DHPG-treated cells;
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FIG. 2. HSV released by dually infected cells during drug treat-
ment. Titers were normalized to 106 cells. Symbols: 0, untreated
cells; A, 30 ,uM ACV-treated cells; V, 100 ,uM ACV-treated cells;
*, 30 ,uM DHPG-treated cells; O, 100 ,uM DHPG-treated cells.
resistant to DHPG and ACV, as is clearly shown in Fig. 3.
The ED50 for HSV recovered from 30 F.M ACV-treated cells
increased from 3.5 to 250 ,uM when assayed in the presence
of ACV and from 1.5 to 220 ,uM when assayed in the
presence of DHPG. For virus from 100 FM ACV-treated
cells, the ED50 rose to 100 ,uM in the presence of ACV and
150 ,uM in the presence of DHPG. The ED50 for HSV from
cells exposed to 30 ,uM DHPG rose to 85 ,uM in the presence
ofACV and 500 ,uM in the presence of DHPG. Development
of resistant HSV was further confirmed by plaque autoradi-
ography (16), which revealed that most virus produced
reduced levels of thymidine kinase (TK) (data not shown).
Despite the increase in infectious virus released into the
supernatant fluids, the percentage of cells producing glyco-
protein C remained less than 10% for the 70 days of drug
therapy, suggesting that fewer cells were producing more
virus. Upon release from the drug, the percentage of cells
making antigen gradually rose to control levels (data not
shown).
Previous studies showed that resistant HSV develops on
repeated passage in cell monolayers in the presence initially
of up to 27 FM ACV through selection for resistance
mediated by an altered TK or TK-negative state (4, 10, 20,
22). In contrast, the HSV in our persistently infected cell line
was able to develop resistance when exposed to the much
higher dose of 100 ,uM ACV. A persistently infected cell
population could continue to generate mutants in the pres-
ence of the drug. Cross-resistance of HSV to DHPG and
ACV (3) has occurred when the mechanism of resistance
involved an altered TK or TK-negative condition, but cross-
resistance was not an invariable consequence. The differ-
ences in the rapidity of development of drug resistance may
indicate differences in the metabolism of DHPG and ACV
(12). ACV triphosphate is a chain terminator (8), whereas
DHPG triphosphate is incorporated internally into replicat-
ing HSV DNA (2). ACV triphosphate is believed to form an
irreversible complex with HSV DNA polymerase (11).
No infectious virus was detected in 100 FM DHPG-treated
cells beginning at 14 days and continuing throughout treat-
ment and for 360 days after release of the cells from the drug
(Fig. 2), nor was glycoprotein C found in the cells. Induction
of HSV production was attempted in the cells which had
been exposed to 100 ,uM DHPG by using 12-O-tetra-
decanoyl-phorbol-13-acetate (30 ng/ml) or 5-bromo-2-
deoxyuridine (50 mg/ml). Despite an increase of EBV capsid
antigen from 1 to 70%, no HSV was released into the
supernatant fluid, nor was HSV glycoprotein C made.
In an effort to determine whether HSV sequences were
retained in the cell line which had been exposed to 100 ,uM
DHPG, DNA was isolated from cells 2 and 6 months after
release from the drug. We were able to detect less than one
copy of the HSV genome per cell in our control reconstruc-
tions. However, probes made with HSV EcoRI fragments F,
A, L, M, 0, and G and BamHI fragment Q, representing
42% of the HSV genome, failed to disclose residual HSV
DNA in cells 2 and 6 months after release from DHPG at our
limits of sensitivity (Fig. 4). All probes had a specific activity
of 2 x 107 to 9.9 x 108 cpm/,ug. Since HSV was continuously
produced by the cell line for years before treatment with 100
FiM DHPG, it is likely that this result was directly due to
drug exposure. One possible explanation for this cure is that
cells infected with HSV are more susceptible to the toxic
effects of DHPG. Another possibility is that, unlike EBV,
perhaps all of the HSV present in the cells is replicated by
viral DNA polymerase, and treatment with 100 ,uM DHPG
was able to eradicate the HSV infection.
During drug treatment, the effects of DHPG and ACV on
EBV genomes in dually infected cells were determined by
DRUG CONCENTRATION (MM)
FIG. 3. Determination of ED50 for resistant HSV isolated from
dually infected cells during drug treatment. Supernatant fluid col-
lected on day 35 was diluted to 1,250 HSV PFU/ml and titrated
against dilutions of DHPG (A) or ACV (B) or no drug. Source of
virus: 0, untreated cells; A, 30 ,uM ACV-treated cells; V, 100 ,uM
ACV-treated cells; *, 30 ,uM DHPG-treated cells.
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FIG. 4. Analysis of HSV DNA in cell lines. DNA was isolated
from cells which had been exposed to 100 ,uM DHPG 2 and 6 months
after release from the drug (lanes 6 and 7). About 4 ,ug of DNA was
digested with EcoRI, electrophoresed in a 0.7% agarose gel, trans-
ferred to nitrocellulose, and hybridized with 32P-labeled HSV DNA
EcoRI fragment G at 1.4 x 101 cpm/,ug. Lanes 1, 3, and 4,
Hybridization to 100, 10, and 1 copy of HSV DNA, respectively;
lanes 2 and 5, empty.
xcRNA-DNA hybridization with an EBV-specific probe.
Copies of the EBV genome fluctuated from 125 to 305 per
cell over time in the untreated control cells. A previous
study indicated that variation was not unusual for P3HR-1
cells, the parent line of our dually infected cells, monitored
over the course of 4 months and at different phases of cell
growth (14). Similar to results of our earlier work (13, 15),
the numbers of genomes were suppressed with drug treat-
ment and remained so with continuous presence of the drug
for 70 days. The number of EBV genomes dropped to 25 or
50 copies per cell by day 14 when exposed to 100 or 30 ,M
DHPG, respectively. ACV at levels of 30 and 100 FiM
similarly reduced the number of copies of the EBV genome
(data not shown).
After centrifugation of the control cells and suspension in
fresh medium, the number of EBV genomes fell from 120 to
75, as determined 28 days after resuspension; this effect was
probably due to logarithmic growth of the cells, which
reduces virus production (14). In the drug-free medium, the
number of EBV genomes then rapidly increased to 270
copies per cell 66 days after resuspension. However, in cells
treated with 30 pLM DHPG or ACV or 100 ,LM DHPG, the
number of EBV genome copies increased but did not rise to
control levels, remaining at 70 to 170 copies 66 days after
resuspension in drug-free medium.
ACV and DHPG both act only on actively replicating
EBV. EBV plasmids in the nonproductive fraction of
P3HR-1 cells are not affected, thus accounting for the
residual copy numbers (15). One of the interesting features
of drug treatment of cell lines persistently infected with EBV
is that the speed of recovery of virus production after
removal of the drug differs from drug to drug (13, 15),
probably because of differences in metabolism of the drugs
(12). The present results show a similar behavior, with much
slower recovery of EBV replication after removal from
DHPG or ACV (data not shown). In a previous study with
P3HR-1 cells (15), the number of EBV genomes eventually
reached control levels when the cells were released from
ACV or DHPG.
It is useful to speculate on the mechanism of resistance of
HSV in the presence of continued suppression of EBV. Both
ACV and DHPG must be phosphorylated to act on viral-
encoded DNA polymerase. Previous work showed that ACV
and DHPG are monophosphorylated by HSV TK (8, 9).
There is increasing evidence of an EBV-encoded TK. There
are rudimentary HSV TK sequences in the EBV genome (1).
Three groups recently reported detection of an EBV-induced
TK (la, 7, 23). In our system, HSV develops resistance by
mutating to an altered TK or a TK-negative state. However,
DHPG and ACV remain active against EBV in the same cells
in which they are presumably less phosphorylated and
inactive against HSV. Thus, the EBV DNA polymerase
must be much more sensitive than the HSV DNA polymer-
ase to the low level of ACV triphosphate made by host
enzymes (6, 17). Perhaps the best explanation is that EBV
produced in P3HR-1 cells arises from a clone of latently
infected cells. In latent cells, EBV is in an episomal form
which does not use virally encoded polymerase to replicate
and thus is not affected by the antiviral drugs (15). The HSV
produced comes from a mixed population of virus from
persistently infected cells, from which resistant virus can be
selected by drug exposure.
We have demonstrated that the use of the dually infected
line is a convenient and predictable method by which drug-
resistant HSV mutants can be generated. Since simultaneous
active infection with two or three different herpesviruses is
not unusual in immunocompromised patients, this dually
infected cell system is a useful in vitro model for the study of
antiviral chemotherapy. This cell system also offers a chance
to study the interaction of HSV and EBV during drug
treatment. Finally, unlike EBV, HSV was eradicated by
treatment with a high dose (100 ,uM) of DHPG. Thus, the
dually infected cell line is potentially useful to screen anti-
viral agents aimed not merely at suppression of viral repli-
cation but at eradication of persistent infection.
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